• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    CDT Equity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    3/9/26 4:05:49 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CDT alert in real time by email
    false 0001896212 0001896212 2026-03-03 2026-03-03 0001896212 CDT:CommonStock0.0001ParValuePerShareMember 2026-03-03 2026-03-03 0001896212 CDT:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockMember 2026-03-03 2026-03-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): March 3, 2026

     

    CDT Equity Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41245   87-3272543
    (State or other jurisdiction   (Commission   (I.R.S. Employer
    of incorporation)   File Number)   Identification No.)

     

    4851 Tamiami Trail North, Suite 200, Naples, FL   34103
    (Address of principal executive offices)   (Zip Code)

     

    (646) 491-9132

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, $0.0001 par value per share   CDT   The Nasdaq Stock Market LLC
    Redeemable Warrants, each whole warrant exercisable for one share of Common Stock   CDTTW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     
     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    Amendment to Directed Stock Purchase Agreement

     

    As previously disclosed on January 22, 2026, CDT Equity Inc. (the “Company”), is party to a directed stock purchase agreement (the “Purchase Agreement”) with an institutional investor (the “Purchaser”) relating to an equity line of credit facility (the “ELOC”).

     

    On March 3, 2026, the Company and Purchaser entered into an amendment to the Purchase Agreement (the “Amendment”) in which the parties mutually agreed to lower the Floor Price (as defined in the Purchase Agreement) to $0.60. Accordingly, the maximum number of shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”) issuable pursuant to the ELOC, not taking into account the beneficial ownership limitations contained in the Purchase Agreement, is 41,666,667 shares. The full issuance of such shares underlying the ELOC is subject to stockholder approval under applicable rules and regulations of The Nasdaq Stock Market LLC.

     

    Senior Secured Convertible Promissory Note

     

    On March 3, 2026, the Company entered into a Securities Purchase Agreement (the “Note Purchase Agreement”) with the Purchaser. Pursuant to the terms of the Note Purchase Agreement, the Company issued a Senior Secured Convertible Promissory Note with a total principal amount of up to $555,556 (the “Note”). The Note bears interest at an annual rate of 10% and matures on July 3, 2026 (the “Maturity Date”). The Company and the Purchaser may mutually agree to extend the Maturity Date by a period of two months.

     

    The Purchaser has the right, but not the obligation, to convert, at any time following Stockholder Approval (as defined below) and prior to the Maturity Date, all or any portion of the outstanding principal amount, into shares (the “Conversion Shares”) of the Company’s Common Stock. The “Conversion Price” shall be equal to the Nasdaq official closing price of the Company’s Common Stock on the Stockholder Approval Date (as defined below). The Note may be prepaid in whole upon ten (10) days’ prior written notice to the Purchaser, but must be prepaid the next business day following a public or private offering, or issuance of Common Stock conducted by the Company, subject to certain customary conditions. Additionally, the Note is secured by certain assets of the Company, pursuant to a security agreement that was entered into with the Purchaser, in connection with the issuance of the Note (the “Security Agreement”). Lastly, to further secure the Company’s obligations pursuant to the Note, a Guaranty Agreement (the “Guaranty”) was entered into by the Company, in favor of the Purchaser. The Purchaser is prohibited from converting an amount that would be convertible into that number of Conversion Shares which would exceed the difference between the number of shares of the Company’s Common Stock beneficially owned by the Purchaser and 9.99% of the outstanding shares of the Company’s Common Stock.

     

    The issuance of any or all of the Conversion Shares is subject to stockholder approval under applicable rules and regulations of The Nasdaq Stock Market LLC, to the extent required by such rules and regulations (“Stockholder Approval” and the date on which Stockholder Approval is received and deemed effective, the “Stockholder Approval Date”). The Company has agreed to convene a stockholders’ meeting on or before May 3, 2026 to approve the issuance of the Conversion Shares.

     

     
     

     

    The above descriptions of the terms and conditions of the Form of the Note, the Note Purchase Agreement, the Security Agreement, and the Guaranty, do not purport to be complete, and are qualified in their entirety by reference to the full text of such agreements and instruments, which are attached to this Current Report on Form 8-K as Exhibits 4.1, 10.2, 10.3, and 10.4, respectively, and are incorporated by reference herein.

     

    Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

     

    The information set forth in Item 1.01 of this Current Report on Form 8-K is hereby incorporated by reference into this Item 2.03 in its entirety.

     

    Item 3.02 Unregistered Sales of Equity Securities

     

    The information set forth in Item 1.01 of this Current Report on Form 8-K is hereby incorporated by reference into this Item 3.02 in its entirety. The issuance of the shares of Common Stock under the Purchase Agreement and the Conversion Shares under the Note will be pursuant to Section 4(a)(2) under the Securities Act of 1933, as amended.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description
    4.1   Form of Senior Secured Convertible Promissory Note, by and between the Company and the Purchaser, dated March 3, 2026
    10.1   Form of Amendment to Equity Purchase Agreement, dated March 3, 2026
    10.2   Note Purchase Agreement, by and between the Company and the Purchaser, dated March 3, 2026
    10.3   Security Agreement, by and between the Company and the Purchaser, dated March 3, 2026
    10.4   Guaranty, by and between the Company and the Purchaser, dated March 3, 2026
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      CDT EQUITY INC.
         
    March 9, 2026 By: /s/ Andrew Regan
      Name: Andrew Regan
      Title: Chief Executive Officer

     

     

     

     

    Get the next $CDT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CDT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CDT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Farley Chele Chiavacci was granted 10,553 shares, increasing direct ownership by 160% to 17,157 units (SEC Form 4)

    4 - CDT Equity Inc. (0001896212) (Issuer)

    2/23/26 8:27:01 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Regan Andrew was granted 224,800 shares (SEC Form 4)

    4 - CDT Equity Inc. (0001896212) (Issuer)

    12/22/25 4:05:28 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Regan Andrew was granted 1,120,000 shares, increasing direct ownership by 2,545,455% to 1,120,044 units (SEC Form 4)

    4 - CDT Equity Inc. (0001896212) (Issuer)

    9/22/25 4:29:05 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CDT Equity Notes Sarborg Filing of U.S. Provisional Patent Application for AI Signature Agent

    NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 05, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company") today notes the announcement issued by Sarborg Limited ("Sarborg") regarding the filing of a U.S. provisional patent application relating to its proprietary AI Signature Agent. CDT holds a 20% equity stake in Sarborg and views this filing as an important step in strengthening and formalising Sarborg's intellectual property position. Sarborg announced that a provisional patent application was filed with the United States Patent and Trademark Office on February 12, 2026, and has been assigned United States Patent Application No. 63/981,801. The application re

    3/5/26 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CDT Positions for Transformational Growth

    NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 04, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company") advances multiple initiatives designed to enhance shareholder value and expand its strategic footprint. The Company continues to actively develop and expand its pharmaceutical asset portfolio, including solid-form and cocrystal development programs, alongside its licensed clinical assets AZD1656, AZD5658 and AZD5904 under its agreement with AstraZeneca. CDT remains engaged in ongoing evaluation and out-licensing discussions and continues to assess pathways to maximize the commercial and strategic potential of these assets. The Company believes this diversifi

    3/4/26 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CDT Equity Notes Sarborg Expansion into Bacteria and Agrochemicals

    NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 24, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today notes the announcement issued this morning by Sarborg Limited regarding the expansion of its proprietary AI Signature Agent platform beyond pharmaceuticals into bacteria and agrochemicals. CDT holds a significant 20% equity stake in Sarborg and views this expansion as a meaningful strategic development in the continued evolution of Sarborg's cross-industry signature intelligence platform. Sarborg announced that, following the successful deployment of its Pharmaceutical Signature Agent, it has curated approximately 4,500 agrochemical signatures and app

    2/24/26 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDT
    SEC Filings

    View All

    CDT Equity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - CDT Equity Inc. (0001896212) (Filer)

    3/9/26 4:05:49 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by CDT Equity Inc.

    DEF 14A - CDT Equity Inc. (0001896212) (Filer)

    3/6/26 4:12:21 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CDT Equity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - CDT Equity Inc. (0001896212) (Filer)

    2/24/26 5:11:37 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDT
    Financials

    Live finance-specific insights

    View All

    CDT Acquires Strategic Stake in Sarborg to Transform its AI-Driven Asset Strategy

    NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 20, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced that it has entered into a strategic transaction to acquire a 20% equity stake in Sarborg Limited ("Sarborg"), an agentic AI signature intelligence business operating across multiple industrial sectors. The investment formalizes and deepens the existing collaboration between CDT and Sarborg, which has already supported the evaluation of CDT's clinical assets through Sarborg's proprietary signature analysis and artificial intelligence capabilities. Sarborg's business is built on the principle that biological, chemical and industrial signatures

    2/20/26 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CDT Equity Increases Bitcoin Holding

    NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 17, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced the acquisition of 9.25648743 Bitcoin ("BTC") for an aggregate purchase price of $1,005,000 (gross of fees), at an average acquisition price of $108,301.75 per BTC. Following this transaction, CDT's total Bitcoin holdings now stand at 17.9090111 BTC. This acquisition marks a continued execution of CDT's cryptocurrency treasury reserve strategy, aimed at diversifying the Company's balance sheet and enhancing long-term shareholder value through the prudent accumulation of digital assets. "CDT remains committed to strategically deploying capita

    10/17/25 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Conduit Pharmaceuticals Files New Patents Following AI-Driven Combination Discoveries

    Includes Conduit's first composition of matter patent filing for AZD5658 and multiple new combination filings for AZD1656 and AZD5658Patents derived from AI-led analysis conducted in partnership with Sarborg Limited NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 07, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit" or the "Company") today announces the filing of four new patent applications relating to its key assets AZD1656 and AZD5658, including the Company's first patent filings for AZD5658. These filings represent a significant expansion of Conduit's intellectual property portfolio, further supporting its strategy to advance and license differentiated, IP

    7/7/25 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDT
    Leadership Updates

    Live Leadership Updates

    View All

    Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors

    Conduit Pharmaceuticals strengthens its Board of Directors with the addition of Simon Fry, a seasoned investment banking executive with over 30 years of experience in asset management, capital markets, and strategy development. NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit" or the "Company"), a multi-asset, clinical stage, disease-agnostic life science company delivering an efficient model for compound development, today announces the appointment of Simon Fry to its Board of Directors. Mr. Fry has over 30 years' experience in investment banking having held senior executive positions at various top-tier in

    11/19/24 4:30:00 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Conduit Pharmaceuticals to Join Russell 3000® Index

    SAN DIEGO and LONDON, June 13, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) (the "Company" or "Conduit"), today announced the Company is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted by FTSE Russell on Friday, May 24th, 2024. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automat

    6/13/24 8:00:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer

    Conduit also appoints prominent intellectual property attorney Jeffrey Lindeman as a Consultant Leadership additions underscore Conduit's commitment to strengthening and broadening its intellectual property portfolio through solid-form technology to maximize future value SAN DIEGO and LONDON, March 19, 2024 (GLOBE NEWSWIRE) --  Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today announced the appointment of Dr. Joanne Holland as Chief Scientific Officer. Dr. Holland brings over 20 years of experience to the CSO role at Conduit, having amassed expertise across the entire development spectrum. This includes a deep knowledge base in ide

    3/19/24 7:00:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Conduit Pharmaceuticals Inc.

    SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)

    11/6/24 6:01:49 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Conduit Pharmaceuticals Inc.

    SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)

    10/18/24 4:15:06 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Conduit Pharmaceuticals Inc.

    SC 13G - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)

    10/11/24 6:01:23 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care